Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07100782 · ClinicalTrials.gov registry record · Phase 3
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
A Phase 3 study of Endometriosis and Pelvic Pain, sponsored by University of Michigan.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 130
- Enrollment target
- 1
- Study location
NCT07100782: Recruiting Phase 3 study of Endometriosis and Pelvic Pain, sponsored by University of Michigan.
NCT07100782 is a Phase 3 study of Endometriosis and Pelvic Pain that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 130 participants, below the 262-participant average among 48 other Endometriosis trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07100782, a Phase 3 study of Endometriosis and Pelvic Pain, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 130 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.
Primary Outcome
LPS-stimulated MIP1-α levels measured from whole blood
Conditions Studied
Interventions
- DRUG Relugolix CT
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-12-08 |
| Est. Completion | 2028-09 |
| Phase | Phase 3 |
What NCT07100782 shows while recruiting
NCT07100782 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 262-participant average among 48 other Endometriosis trials with a reported enrollment target (50% lower).
The record links to 2 conditions, with Endometriosis appearing as the primary indexed condition, and to 1 intervention - of which Relugolix CT is the first listed.
NCT07100782 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07100782 about?
NCT07100782 is a clinical study titled "Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain". The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.
What is the current status of trial NCT07100782?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2025-12-08. Estimated completion is 2028-09.
What conditions does trial NCT07100782 study?
This clinical trial studies the following conditions: Endometriosis, Pelvic Pain.
What interventions are being tested in trial NCT07100782?
The interventions under investigation include: Relugolix CT (DRUG).
Who is sponsoring clinical trial NCT07100782?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07100782 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometriosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07100782's enrollment target sits among peer trials
130 16th of 48 higher than 33 of 48 other Endometriosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometriosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
RECRUITING · Phase 3
-
The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial
RECRUITING · Phase 3
-
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
RECRUITING · Phase 3
-
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
ACTIVE NOT RECRUITING · Phase 3
-
SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain
COMPLETED · Phase 3
-
Medical Treatment of Endometriosis-Associated Pelvic Pain
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI